Why a third receptor matters in the research
Adding glucagon-receptor activity to GIP and GLP-1 agonism changes which metabolic pathways a study can observe at once. That is the specific question the retatrutide literature is built around.
Because retatrutide is newer, there is far less independent published work than for tirzepatide. Researchers choosing between them are usually trading breadth of mechanism against depth of comparable prior data.
Purity matters more on newer compounds
Newer compounds attract more low-quality supply, because fewer buyers know what a correct CoA looks like. Every retatrutide and tirzepatide lot we sell is independently HPLC assayed and mass-spec confirmed, and the lot number on the vial matches the certificate.
If a supplier cannot produce a lot-matched certificate for the exact vial you received, treat the purity claim as unverified.
Questions people ask
- Is retatrutide stronger than tirzepatide?
- They are not directly comparable that way. Retatrutide is a triple agonist and tirzepatide a dual agonist — the receptor coverage differs, and the published data on retatrutide is much newer and thinner.
- Which has more published research behind it?
- Tirzepatide, by a clear margin. Retatrutide's literature base is still building.
- Are both HPLC tested?
- Yes — every lot of both is independently assayed at ≥99% purity with a lot-matched Certificate of Analysis you can look up before you open the vial.